Mechanochemical Ablation Compared to Cyanoacrylate Adhesive
Primary Purpose
Varicose Veins
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Mechanochemical ablation
Cyanoacrylate adhesive
Sponsored by
About this trial
This is an interventional treatment trial for Varicose Veins
Eligibility Criteria
Inclusion Criteria:
- Adults over 18 years of age
- Symptomatic GSV or SSV vein reflux > 0.5 seconds on colour Duplex
Exclusion Criteria:
- Current DVT
- Recurrent varicose veins
- Arterial disease (ABPI<0.8)
- Vein diameter < 3mm
- Patient who are unwilling to participate
- Inability or unwillingness to complete questionnaires
- Adverse reaction to sclerosant or cyanoacrylate
- Not been involved in another venous trial for at least 6 months
Sites / Locations
- Charing Cross Hospital, Imperial College London
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Mechanochemical ablation (MOCA)
Cyanoacrylate adhesive (CAE)
Arm Description
Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
Outcomes
Primary Outcome Measures
Pain Score During Ablation
Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)
Secondary Outcome Measures
Pain Score at the End of the Procedure
Pain score at the end of the procedure using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)
Generic Quality of Life as Per EQ-5D Questionnaire
Using the EuroQoL's EQ-5D questionnaire (-0.085=worse quality of life; 1.000=best quality of life)
Disease Specific Quality of Life as Per the AVVQ
Using the Aberdeen Varicose Vein Questionnaire (AVVQ) questionnaire (0=best quality of life; 100=worse quality of life)
Disease Specific Quality of Life as Per the CIVIQ-20
Using the CIVIQ-20 questionnaire (0=best quality of life; 100=worse quality of life)
Clinical Change as Per VCSS
Using the Venous Clinical Severity Score (VCSS) (0=best; 30=worse)
Pain Score Over the First 10 Days
Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain). The mean pain score was recorded daily and a mean value was calculated.
Degree of Bruising at 2 Weeks
Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment). The outcome measured is the number of participants with a degree of bruising between category 0-1.
Time to Return to Normal Activities
Length of time in days until normal activities are resumed
Occlusion Rates
Rate of occlusion as assessed by duplex ultrasound
Full Information
NCT ID
NCT03392753
First Posted
November 28, 2017
Last Updated
August 3, 2022
Sponsor
Imperial College London
Collaborators
Singapore General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03392753
Brief Title
Mechanochemical Ablation Compared to Cyanoacrylate Adhesive
Official Title
Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
November 6, 2017 (Actual)
Primary Completion Date
July 31, 2019 (Actual)
Study Completion Date
December 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
Singapore General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study will be comparing the treatment of varicose veins using either mechanochemical ablation (MOCA) or cyanoacrylate adhesive (CAE). Patients will be randomised to receiving either MOCA or CAE.
The pain scores, clinical scores, quality of life scores, occlusion and re-intervention rate at 2 weeks, 3, 6 and 12 months as well as the cost effectiveness of each intervention will be assessed.
Detailed Description
This will be a randomised clinical trial comparing MOCA to CAE. Patients will be randomised into group A (MOCA) or group B (CAE). Only the endovenous ablation part of the procedure will be randomised while the decision as to whether patients should receive treatment of their varicose tributaries will be at the discretion of the clinical team.
The device used for MOCA (group A) will be the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
The device used for CAE (group B) will be the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
Re-intervention of the treated saphenous veins will not be decided until at least 3 months after their initial procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Varicose Veins
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
An internet-based randomisation service will be used Outcome assessors will be blinded as to treatment offered
Allocation
Randomized
Enrollment
167 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mechanochemical ablation (MOCA)
Arm Type
Active Comparator
Arm Description
Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
Arm Title
Cyanoacrylate adhesive (CAE)
Arm Type
Active Comparator
Arm Description
Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
Intervention Type
Procedure
Intervention Name(s)
Mechanochemical ablation
Intervention Description
Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
Intervention Type
Procedure
Intervention Name(s)
Cyanoacrylate adhesive
Intervention Description
Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
Primary Outcome Measure Information:
Title
Pain Score During Ablation
Description
Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)
Time Frame
On day 0 immediately following vein ablation
Secondary Outcome Measure Information:
Title
Pain Score at the End of the Procedure
Description
Pain score at the end of the procedure using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)
Time Frame
On day 0 following vein ablation and any tributary treatment
Title
Generic Quality of Life as Per EQ-5D Questionnaire
Description
Using the EuroQoL's EQ-5D questionnaire (-0.085=worse quality of life; 1.000=best quality of life)
Time Frame
Recorded at 12 months
Title
Disease Specific Quality of Life as Per the AVVQ
Description
Using the Aberdeen Varicose Vein Questionnaire (AVVQ) questionnaire (0=best quality of life; 100=worse quality of life)
Time Frame
Recorded at 12 months
Title
Disease Specific Quality of Life as Per the CIVIQ-20
Description
Using the CIVIQ-20 questionnaire (0=best quality of life; 100=worse quality of life)
Time Frame
12 months
Title
Clinical Change as Per VCSS
Description
Using the Venous Clinical Severity Score (VCSS) (0=best; 30=worse)
Time Frame
12 months
Title
Pain Score Over the First 10 Days
Description
Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain). The mean pain score was recorded daily and a mean value was calculated.
Time Frame
For the first 10 days since procedure
Title
Degree of Bruising at 2 Weeks
Description
Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment). The outcome measured is the number of participants with a degree of bruising between category 0-1.
Time Frame
2 weeks
Title
Time to Return to Normal Activities
Description
Length of time in days until normal activities are resumed
Time Frame
2 weeks
Title
Occlusion Rates
Description
Rate of occlusion as assessed by duplex ultrasound
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults over 18 years of age
Symptomatic GSV or SSV vein reflux > 0.5 seconds on colour Duplex
Exclusion Criteria:
Current DVT
Recurrent varicose veins
Arterial disease (ABPI<0.8)
Vein diameter < 3mm
Patient who are unwilling to participate
Inability or unwillingness to complete questionnaires
Adverse reaction to sclerosant or cyanoacrylate
Not been involved in another venous trial for at least 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alun H Davies
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charing Cross Hospital, Imperial College London
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35385061
Citation
Belramman A, Bootun R, Tang TY, Lane TRA, Davies AH. Pain Outcomes Following Mechanochemical Ablation vs Cyanoacrylate Adhesive for the Treatment of Primary Truncal Saphenous Vein Incompetence: The MOCCA Randomized Clinical Trial. JAMA Surg. 2022 May 1;157(5):395-404. doi: 10.1001/jamasurg.2022.0298.
Results Reference
derived
PubMed Identifier
30086774
Citation
Belramman A, Bootun R, Tang TY, Lane TRA, Davies AH. Mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins: study protocol for a randomised controlled trial. Trials. 2018 Aug 7;19(1):428. doi: 10.1186/s13063-018-2807-0.
Results Reference
derived
Learn more about this trial
Mechanochemical Ablation Compared to Cyanoacrylate Adhesive
We'll reach out to this number within 24 hrs